Oxford BioMedica
Discover Realise

Non-Executive Directors

Dr. Lorenzo Tallarigo

Chairman

Dr. Lorenzo Tallarigo was appointed as Non-Executive Chairman of the Group in February 2016. From 2008 to 2014 he was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept’s NASDAQ IPO in 2012 was one of the most successful ever. From 2009 to 2014, he held the position of Chief Executive Officer and is still a Board member at Genextra, a holding company focused on identifying innovative research and projects in life sciences to develop novel treatments and tools by creating successful business ventures. From 1985 to 2008, he worked at Eli Lilly, where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, and latterly as its President of international operations. He has a Doctor of Medicine degree from the University of Pisa (Italy) and a PMD from Harvard Business School in Boston. 

Dr. Lorenzo Tallarigo

Andrew Heath

Deputy Chairman and Senior Independent Director

Dr Andrew Heath was appointed to Oxford BioMedica's Board in January 2010 and was appointed Deputy Chairman and Senior Independent Director in May 2011. Dr Heath is a healthcare and biopharmaceutical executive with in-depth knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr Heath was President and Chief Executive Officer of Aerogen Inc., and previously held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. He is currently a non-executive director of XL TechGroup Inc., Anew Inc., Pioneer Technology Inc., and was a director of the BioIndustry Association.

Andrew Heath

Martin Diggle

Non-Executive Director

Martin Diggle was appointed to Oxford BioMedica’s Board in October 2012. Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxford BioMedica’s largest shareholder. An investment professional with over 30 years’ experience in investment banking and fund management, Martin has extensive, first-hand knowledge of the global financial markets. Martin is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade.  Mr Diggle holds a master’s degree in Philosophy, Politics and Economics from University of Oxford.

Martin Diggle

Stuart Henderson

Independent Non-executive Director

Stuart Henderson was appointed a Non-executive Director and Chair of the Audit Committee in June 2016. Mr. Henderson was a partner at Deloitte, where he was Head of European Healthcare and Life Sciences and also served on the Global Industry Team for seven years between 2004 and 2011. Prior to this he was Partner at Arthur Andersen from 1982 to 2002, where he sat on the Andersen Global Life Sciences Team as Head of Emerging Biotechnology. Mr. Henderson has extensive experience in audit and transaction support practice and has worked with life science businesses from start up to multinational as well as acting as reporting accountant on numerous IPO and Class 1 transactions. He has reported as Audit Partner to the audit committees of publicly quoted companies for over 20 years. Mr. Henderson is a former director of the Babraham Institute and currently sits as an observer on the board of OneNucleus, the Life Sciences trade body for Cambridge and London.